218 related articles for article (PubMed ID: 35068786)
21. Saroglitazar in Non-alcoholic Fatty Liver Disease From Bench to Bedside: A Comprehensive Review and Sub-group Meta-Analysis.
Roy A; Tewari B; Giri S; Goenka M
Cureus; 2023 Oct; 15(10):e47493. PubMed ID: 38022283
[TBL] [Abstract][Full Text] [Related]
22. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
[TBL] [Abstract][Full Text] [Related]
23. Biopsy Proven Fibrosis in Non-Alcoholic Fatty Liver Disease: An Analysis of Risk Factors.
Pattnaik K; Bhuyan P; Singh A; Singh SP; Nath P; Kar S; Misra B; Rath J
J Clin Exp Hepatol; 2018 Dec; 8(4):367-374. PubMed ID: 30563997
[TBL] [Abstract][Full Text] [Related]
24. Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.
Chatterjee S; Majumder A; Ray S
Sci Rep; 2015 Jan; 5():7706. PubMed ID: 25573251
[TBL] [Abstract][Full Text] [Related]
25. Interleukin Levels and Non-Alcoholic Fatty Liver Disease in Chronic Plaque Psoriasis: An Analytical Case Control Study.
Yadav V; Mendiratta V; Agrawal A; Bisherwal K; Singh R; Meena AK
Indian J Dermatol; 2023; 68(4):377-384. PubMed ID: 37822394
[TBL] [Abstract][Full Text] [Related]
26. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease.
Anand A; Singh AA; Elhence A; Vaishnav M; Biswas S; Gunjan D; Gamanagatti SR; Nayak B; Kumar R; Shalimar
J Clin Exp Hepatol; 2022; 12(2):362-371. PubMed ID: 35535086
[TBL] [Abstract][Full Text] [Related]
28. Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients.
Siddiqui MS; Parmar D; Shaikh F; Forsgren M; Patel S; Bui AT; Boyett S; Patel V; Sanyal AJ
Liver Transpl; 2023 Sep; 29(9):979-986. PubMed ID: 36847136
[TBL] [Abstract][Full Text] [Related]
29. Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
Patel MR; Kansagra KA; Parikh DP; Parmar DV; Patel HB; Soni MM; Patil US; Patel HV; Patel JA; Gujarathi SS; Parmar KV; Srinivas NR
Clin Drug Investig; 2018 Jan; 38(1):57-65. PubMed ID: 29022212
[TBL] [Abstract][Full Text] [Related]
30. Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.
Kothari S; Dhami-Shah H; Shah SR
J Clin Exp Hepatol; 2019; 9(6):723-730. PubMed ID: 31889754
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies.
Chhabra M; Vidyasagar K; Gudi SK; Sharma J; Sharma R; Rashid M
PLoS One; 2022; 17(7):e0269531. PubMed ID: 35776741
[TBL] [Abstract][Full Text] [Related]
32. Association between resistin +299A/A genotype and nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus.
Zhang LY; Jin YJ; Jin QS; Lin LY; Zhang DD; Kong LL
Gene; 2013 Oct; 529(2):340-4. PubMed ID: 23954219
[TBL] [Abstract][Full Text] [Related]
33. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
[TBL] [Abstract][Full Text] [Related]
34. Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link?
Jain S; Thanage R; Panchal F; Rathi PM; Munshi R; Udgirkar SS; Contractor QQ; Chandnani SJ; Sujit NP; Debnath P; Singh A
J Clin Exp Hepatol; 2021; 11(4):466-474. PubMed ID: 34276153
[TBL] [Abstract][Full Text] [Related]
35. Gender impacts on the correlations between nonalcoholic fatty liver disease and hypertension in a Chinese population aged 45-60 y.
Li XD; Qiu BH; Su FC; Sun SX
Clin Exp Hypertens; 2016; 38(7):639-643. PubMed ID: 27680771
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Zhou ST; Cui W; Kong L; Yang X
Curr Med Sci; 2022 Jun; 42(3):513-519. PubMed ID: 35451807
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the anti-inflammatory and antilipidemic activity of diosmin and saroglitazar in a model of nonalcoholic fatty liver induced by a high-fat diet in Wistar rats.
Afarin R; Dinarvand N; Jaberian Asl B; Orak G; Shakerian E; Bineshfar F; Ahangarpour A
Iran J Basic Med Sci; 2024; 27(2):241-246. PubMed ID: 38234671
[TBL] [Abstract][Full Text] [Related]
38. Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease.
Ishikawa T; Terai N; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
Intern Med; 2024 Feb; ():. PubMed ID: 38346734
[TBL] [Abstract][Full Text] [Related]
39. Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.
Bhosle D; Bhosle V; Bobde J; Bhagat A; Shaikh H; Kadam R
J Assoc Physicians India; 2018 Mar; 66(3):14-7. PubMed ID: 30341861
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Adverse Effect of Liver Stiffness on Glycaemic Control in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study.
Mantovani A; Taverna A; Cappelli D; Beatrice G; Csermely A; Sani E; Byrne CD; Targher G
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
